Medicine
Sodium Phosphates 7100 mg/13800 mg per 50 mL injection
Sodium Phosphates 7100 mg/13800 mg per 50 mL injection is a prescription medicine containing Sodium phosphate, dibasic, and Sodium phosphate, monobasic, for intravenous use, marketed by American Regent, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20 to 25°C (68 to 77°F).
Key facts
- Active ingredient (INN)
- Sodium phosphate, dibasic, and Sodium phosphate, monobasic,
- Brand
- Sodium Phosphates
- Strength
- 7100 mg/13800 mg per 50 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 25 vials of 50 mL
- Marketing authorisation holder
- American Regent
- Manufacturer
- American Regent
- Origin register
- US FDA, United States
- Storage
- Store at 20 to 25°C (68 to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 June 2024
- Identifiers
- RxCUI 1872384, 1872443, 1872447DailyMed set ID dc0462ee-4486-418c-865f-e2a71bdb8e9eNDC 0517-7350Application ANDA218314
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 25 vial, single-dose in 1 tray / 50 mL in 1 vial, single-dose | 0517-7350-25 | American Regent | 21 June 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 May 1983 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Sodium phosphate, dibasic, and Sodium phosphate, monobasic, 7100 mg/13800 mg per 50 mL injection.
Other strengths and forms of Sodium phosphate, dibasic, and Sodium phosphate, monobasic,
Clinical summary
Sodium phosphate, dibasic, and Sodium phosphate, monobasic, is a fixed-dose combination medicine indicated as a source of phosphorus, for addition to large volume intravenous fluids, among other approved uses. MedsAcross supplies Sodium phosphate, dibasic, and Sodium phosphate, monobasic, for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Sodium phosphate, dibasic, and Sodium phosphate, monobasic,For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sodium Phosphates prescribing information (Hospira) · U.S. National Library of Medicine, DailyMed
Need Sodium Phosphates 7100 mg/13800 mg per 50 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.